ArticleDrug delivery and translational research2020
A chitosan film containing quercetin-loaded transfersomes for treatment of secondary osteoporosis.
Article in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 50 citations in OpenAlex.
- Dihydromyricetin-LoadedPharmaceutics · 2026Article
- Identification of Chronic Stress-Related Biomarkers for Potential Diagnosis and Treatment of Osteoporosis: An Integrated Multi-omic and Clinical Data Analysis.Therapeutic innovation & regulatory science · 2026Article
- Engineering Bilosomal Nanocarriers for Targeted Delivery of Resveratrol: Rational Design, Radiotracking Insights and Cytotoxic Assessment.AAPS PharmSciTech · 2026Article
- Quercetin in bone regeneration: optimization of drug delivery system and study of its synergistic mechanism with bone tissue engineering.Frontiers in pharmacology · 2026Review
- Current Approaches on Transfersomal Patch: A Noninvasive Innovative Booster for Improved Transdermal Drug Delivery.Current pharmaceutical biotechnology · 2025Review
- Overcoming Skin Barrier with Transfersomes: Opportunities, Challenges, and Applications.Current drug delivery · 2025Review
- Osteoporosis: Causes, Mechanisms, Treatment and Prevention: Role of Dietary Compounds.Pharmaceuticals (Basel, Switzerland) · 2024Review
- An Overview of Film-Forming Emulsions for Dermal and Transdermal Drug Delivery.AAPS PharmSciTech · 2024Review
- Plant-Based Nanovesicular Gel Formulations Applied to Skin for Ameliorating the Anti-Inflammatory Efficiency.Gels (Basel, Switzerland) · 2024Review
- Quercetin in Osteoporosis Treatment: A Comprehensive Review of Its Mechanisms and Therapeutic Potential.Current osteoporosis reports · 2024Review
- Pharmacological and mechanistic aspects of quercetin in osteoporosis.Frontiers in pharmacology · 2024Review
- Quercetin as a Therapeutic Product: Evaluation of Its Pharmacological Action and Clinical Applications-A Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- Box-Behnken Design: Optimization of Proanthocyanidin-Loaded Transferosomes as an Effective Therapeutic Approach for Osteoarthritis.Nanomaterials (Basel, Switzerland) · 2022Article
- Formulation and Evaluation of Topical Nano-Lipid-Based Delivery of Butenafine: In Vitro Characterization and Antifungal Activity.Gels (Basel, Switzerland) · 2022Article
- Improved Bioavailability of Ebastine through Development of Transfersomal Oral Films.Pharmaceutics · 2021Article
- Quercetin as an Agent for Protecting the Bone: A Review of the Current Evidence.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, due to its prevalence worldwide, is a serious health problem. Topical administration of quercetin, a phytoestrogen, in the form of deformable transfersomes, could be used to treat osteoporosis to overcome its low oral solubility and bioavailability. Formulation process of transfersomes was screened by fractional factorial design and further optimized using full factorial design. Transfersomes showed good characteristics such as entrapment efficiency, particle size, zeta potential, and polydispersity index (83.0 ± 2.2%, 75.95 ± 2 nm, - 13.6 ± 6 mv and 0.333, respectively). Transfersomes were further loaded into chitosan film and showed good permeation through rat skin. Further, glucocorticoid-induced osteoporosis rat model showed induction of osteoporosis after day 30. On day 45, treatment with chitosan film containing quercetin-loaded transfersomes showed remarkable rise in femur thickness, length, density as well as in serum biochemical parameters such as calcium, phosphorous, alkaline phosphatase, and tartrate-resistant alkaline phosphatase compared to positive control group. Tensile strength of osteoporotic femur bone was also found to be increased and was comparable with normal group. Histomicrographic analysis of femur bone exhibited less disruptive and lytic changes. Thus, all the above findings indicated the beneficial effects of quercetin-loaded transfersome chitosan film, due to decline in osteoclastogenesis and osteoblast apoptosis, which further favored increase in osteoblast numbers and mineralization of bones. Thus, chitosan film containing quercetin-loaded transfersomes was found to be good alternative to oral administration of quercetin to treat osteoporosis, while easy applicability of film in the form of wrist band anytime, anywhere, and even at work achieve patient compliance. Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.